Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons

Vaccine

Volumn 32, Issue 11, 2014, Pages 1296-1303

  Karmakar, Souvik ^a   Zhang, Weidong ^a   Ahmad, Gul ^b   Torben, Workineh ^c   Alam, Mayeen U ^a   Le, Loc ^a   Damian, Raymond T ^d   Wolf, Roman F ^e   White, Gary L ^e   Carey, David W ^e   Carter, Darrick ^f,g   Reed, Steven G ^f   Siddiqui, Afzal A ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b PERU STATE COLLEGE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^g PAI Life Sciences   (United States)

Author keywords

Baboons; Calpain; Intestinal schistosomiasis; Nonhuman primate; Schistosoma haematobium; Schistosoma mansoni; Schistosome vaccine; Sm p80; Urinary schistosomiasis

Indexed keywords

BABOONS; CALPAIN; INTESTINAL SCHISTOSOMIASIS; NONHUMAN PRIMATE; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOME VACCINE; SM-P80; URINARY SCHISTOSOMIASIS;

ANIMALS; ANTIBODIES, HELMINTH; ANTIBODY FORMATION; ANTIGENS, HELMINTH; CRICETINAE; CROSS PROTECTION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, CELLULAR; MALE; PAPIO; PARASITE EGG COUNT; PILOT PROJECTS; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINES; VACCINES, SYNTHETIC;

EID: 84893980022     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.057     Document Type: Article

References (46)

1. Beaumier C.M., Gillespie P.M., Hotez P.J., Bottazzi M.E. New vaccines for neglected parasitic diseases and dengue. Transl Res 2013, 162(September (3)):144-155.
2. Gryseels B. Schistosomiasis. Infect Dis Clin North Am 2012, 26(June (2)):383-397.
3. Hotez P.J., Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009, 3(8):e412.
4. Rollinson D., Knopp S., Levitz S., et al. Time to set the agenda for schistosomiasis elimination. Acta Trop 2013, 128(November (2)):423-440.
5. Terer C.C., Bustinduy A.L., Magtanong R.V., Muhoho N., Mungai P.L., Muchiri E.M., et al. Evaluation of the health-related quality of life of children in Schistosoma haematobium - endemic communities in Kenya: a cross-sectional study. PLoS Negl Trop Dis 2013, 7(March (3)):e2106.
6. Siddiqui A.A., Siddiqui B.A., Ganley-Leal L. Schistosomiasis vaccines. Hum Vaccin 2011, 7(November (11)):1192-1197.
7. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006, 6(July (7)):411-425.
8. Gryseels B., Polman K., Clerinx J., Kestens L. Human schistosomiasis. Lancet 2006, 368(September (9541)):1106-1118.
9. Kjetland E.F., Leutscher P.D., Ndhlovu P.D. A review of female genital schistosomiasis. Trends Parasitol 2012, 28(February (2)):58-65.
10. Ndeffo Mbah M.L., Poolman E.M., Drain P.K., Coffee M.P., van der Werf M.J., Galvani A.P. HIV and Schistosoma haematobium prevalences correlate in sub-Saharan Africa. Trop Med Int Health 2013, 18(October (10)):1174-1179.
11. Secor W.E. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr Opin HIV AIDS 2012, 7(May (3)):254-259.
12. Siddiqui A.A., Zhou Y., Podesta R.B., Karcz S.R., Tognon C.E., Strejan G.H., et al. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1993, 1181(March (1)):37-44.
13. Silva E.E., Clarke M.W., Podesta R.B. Characterization of a C3 receptor on the envelope of Schistosoma mansoni. J Immunol 1993, 151(December (12)):7057-7066.
14. Young B.W., Podesta R.B. Complement and 5-HT increase phosphatidylcholine incorporation into the outer bilayers of Schistosoma mansoni. J Parasitol 1986, 72(October (5)):802-803.
15. Croall D.E., Ersfeld K. The calpains: modular designs and functional diversity. Genome Biol 2007, 8(6):218.
16. Braschi S., Wilson R.A. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics 2006, 5(February (2)):347-356.
17. Kumagai T., Maruyama H., Hato M., Ohmae H., Osada Y., Kanazawa T., et al. Schistosoma japonicum: localization of calpain in the penetration glands and secretions of cercariae. Exp Parasitol 2005, 109(January (1)):53-57.
18. Zhou Y., Podesta R.B. Effects of serotonin (5HT) and complement C3 on the synthesis of the surface membrane precursors of adult Schistosoma mansoni. J Parasitol 1989, 75(June (3)):333-343.
19. Ahmad G., Zhang W., Torben W., Haskins C., Diggs S., Noor Z., et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009, 105(November (6)):1767-1777.
20. Ahmad G., Zhang W., Torben W., Damian R.T., Wolf R.F., White G.L., et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009, 27(May (21)):2830-2837.
21. Zhang W., Ahmad G., Torben W., Noor Z., Le L., Damian R.T., et al. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 2010, 201(April (7)):1105-1112.
22. Ohta N., Kumagai T., Maruyama H., Yoshida A., He Y., Zhang R. Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol Int 2004, 53(June (2)):175-181.
23. Ohta N., Kumagai T., Maruyama H., Yoshida A., He Y., Zhang R. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun 2001, 69(January (1)):386-391.
24. Ahmad G., Zhang W., Torben W., Ahrorov A., Damian R.T., Wolf R.F., et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J Infect Dis 2011, 204(November (9)):1437-1449.
25. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011, 6(1):e16333.
26. Ahmad G., Torben W., Zhang W., Wyatt M., Siddiqui A.A. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009, 31(March (3)):156-161.
27. Zhang W., Ahmad G., Torben W., Siddiqui A.A. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol 2010, 32(April (4)):252-258.
28. Espitia C.M., Zhao W., Saldarriaga O., Osorio Y., Harrison L.M., Cappello M., et al. Duplex real-time reverse transcriptase PCR to determine cytokine mRNA expression in a hamster model of new world cutaneous leishmaniasis. BMC Immunol 2010, 11:31.
29. Andresen K., Tom T.D., Strand M. Characterization of cDNA clones encoding a novel calcium-activated neutral proteinase from Schistosoma mansoni. J Biol Chem 1991, 266(August (23)):15085-15090.
30. Karcz S.R., Podesta R.B., Siddiqui A.A., Dekaban G.A., Strejan G.H., Clarke M.W. Molecular cloning and sequence analysis of a calcium-activated neutral protease (calpain) from Schistosoma mansoni. Mol Biochem Parasitol 1991, 49(December (2)):333-336.
31. Siddiqui A.A., Podesta R.B., Clarke M.W. Schistosoma mansoni: characterization and identification of calcium-binding proteins associated with the apical plasma membrane and envelope. Exp Parasitol 1991, 72(January (1)):63-68.
32. Fu C.L., Odegaard J.I., Herbert D.R., Hsieh M.H. A novel mouse model of Schistosoma haematobium egg-induced immunopathology. PLoS Pathog 2012, 8(3):e1002605.
33. Ghandour A.M. The development of Schistosoma haematobium in the hamster. Ann Trop Med Parasitol 1978, 72(June (3)):219-225.
34. Vuong P.N., Bayssade-Dufour C., Albaret J.L., Farhati K. Histopathological observations in new and classic models of experimental Schistosoma haematobium infections. Trop Med Int Health 1996, 1(June (3)):348-358.
35. Reid G.D., Sturrock R.F., Harrison R.A., Tarara R.P. Schistosoma haematobium in the baboon (Papio anubis): assessment of protection levels against either a single mass challenge or repeated trickle challenges after vaccination with irradiated schistosomula. J Helminthol 1995, 69(June (2)):139-147.
36. Renganathan E.A., Schaefer K.U., Bickle Q.D. Use of human infection and vaccine-protected baboon sera for the characterisation of cloned Schistosoma haematobium antigen genes. Trop Med Parasitol 1993, 44(September (3)):187-191.
37. Byram J.E., Harrison R.A., Von L.F., Webbe G., Sturrock R.F. Pathology resulting from the administration of a live attenuated anti-Schistosoma haematobium vaccine in baboons. Am J Trop Med Hyg 1989, 40(January (1)):55-65.
38. Avery D.T., Bryant V.L., Ma C.S., de Waal M.R., Tangye S.G. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol 2008, 181(August (3)):1767-1779.
39. Garraud O., Perraut R., Riveau G., Nutman T.B. Class and subclass selection in parasite-specific antibody responses. Trends Parasitol 2003, 19(July (7)):300-304.
40. Tangye S.G., Ferguson A., Avery D.T., Ma C.S., Hodgkin P.D. Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol 2002, 169(October (8)):4298-4306.
41. Mattos A.M., Almeida C.S., Franken K.L., Alves C.C., Abramo C., de Souza M.A., et al. Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol 2010, 22(September (9)):775-782.
42. Ohtani H., Wakui H., Komatsuda A., Okuyama S., Masai R., Maki N., et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004, 19(March (3)):574-579.
43. Ahmad G., Zhang W., Torben W., Noor Z., Siddiqui A.A. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 2010, 14(September (9)):e781-e787.
44. Siddiqui A.A., Phillips T., Charest H., Podesta R.B., Quinlin M.L., Pinkston J.R., et al. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003, 21(June (21-22)):2882-2889.
45. Siddiqui A.A., Phillips T., Charest H., Podesta R.B., Quinlin M.L., Pinkston J.R., et al. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun 2003, 71(July (7)):3844-3851.
46. Zhang W., Ahmad G., Torben W., Siddiqui A.A. Schistosoma mansoni antigen Sm-p80: prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 2011, 118(May (2)):142-151.